Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

32.00
+1.414.61%
Post-market: 32.000.00000.00%19:59 EST
Volume:1.53M
Turnover:48.77M
Market Cap:1.84B
PE:17.86
High:32.30
Open:30.77
Low:30.76
Close:30.59
52wk High:79.18
52wk Low:27.09
Shares:57.44M
Float Shares:38.70M
Volume Ratio:0.97
T/O Rate:3.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.79
EPS(LYR):1.64
ROE:29.74%
ROA:9.38%
PB:4.83
PE(LYR):19.48

Loading ...

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

GlobeNewswire
·
Yesterday

KeyBanc Sticks to Their Buy Rating for ODDITY Tech Ltd. Class A (ODD)

TIPRANKS
·
Yesterday

ODDITY to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

GlobeNewswire
·
Feb 19

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

GlobeNewswire
·
Feb 11

Oddity Tech (ODD) Is Down 8.7% After Il Makiage Slowdown Jitters And MethodIQ Spend Concerns

Simply Wall St.
·
Feb 10

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit

GlobeNewswire
·
Feb 04

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

GlobeNewswire
·
Jan 29

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

GlobeNewswire
·
Jan 28

Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027

Benzinga
·
Jan 28

Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Dow Jones
·
Jan 28

Odd Burger Warns of Imminent Cease Trade Order Over Delayed Annual Filings

TIPRANKS
·
Jan 28

Quoin announces submission to Japanese MHLW for ODD for QRX003

TIPRANKS
·
Jan 27

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

GlobeNewswire
·
Jan 27

LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma

Stock News
·
Jan 22

Dyne announces MHLW in Japan granted ODD for zeleciment basivarsen

TIPRANKS
·
Jan 20

Insider-Favored Growth Stocks To Consider In January 2026

Simply Wall St.
·
Jan 20

Assessing Oddity Tech (ODD) Valuation After Analyst Praise And METHODIQ Skincare Launch

Simply Wall St.
·
Jan 17

Odd Burger Delays Annual Filings After Financing Default Triggers Liquidity Crunch

TIPRANKS
·
Jan 16

ODDITY Tech Secures Expanded $350 Million Credit Facilities to Fund Growth

TIPRANKS
·
Jan 13

Oddity Tech Ltd: Co Has Entered Into Amendments to Existing Agreements With Syndicate of Banks to Secure Credit Facilities for Total of $350 Mln

THOMSON REUTERS
·
Jan 13